XML 43 R25.htm IDEA: XBRL DOCUMENT
v3.25.1

Note 17 - Warrants | 12 Months Ended
--- | ---
Dec. 31, 2024
Notes to Financial Statements |
Warrants Disclosure [Text Block] | Note 17. Warrants Underwriter Warrants In June 2021, the Company issued 144,000 warrants to Maxim Group LLC, the underwriter (the “Underwriter Warrants”) in connection with the June 2021 Public Offering ( “June Offering”). The Underwriter Warrants expire five years from the effective date of the June Offering and are exercisable at a per share price equal to $5.50 per share, or 110% of the public offering price per unit in the June Offering. As of December 31, 2024 and 2023, there were 144,000 and 144,000 Underwriter Warrants issued and outstanding, respectively. Placement Agent Warrants In December 2022, pursuant to the December 2021 Offering, the Company issued warrants to purchase 4,575,429 shares of common stock in an offering, at an exercise price of $1.75 and a term of 3 years. In addition to, but separate from, the unregistered warrants included in the units sold in the December 2021 Offering, the Company issued 549,051 warrants to purchase shares of Common Stock with an exercise price of $1.75 per share, to its Placement Agent Dawson James Securities Inc. The Placement Agent Warrants are exercisable at any time and from time to time during the three-year period commencing on the six-month anniversary of the closing date. As of December 31, 2024 and 2023, there were 1,187,035 and 549,051 Placement Agent Warrants issued and outstanding, respectively. Progressive Care Merger Warrants On October 1, 2024, as a result of the Progressive Care merger with NextPlat, each warrant to purchase Progressive Care common stock that was outstanding and unexercised immediately prior to the effective time of the Merger automatically converted into a warrant to purchase shares of NextPlat common stock with each such warrant having and being subject to the same terms and conditions (including vesting and exercisability terms) as were applicable to such Progressive Care warrant immediately before the effective time. Stock-Based Compensation Warrants There were no stock-based compensation warrants issued for the year ended December 31, 2024. For the year ended December 31, 2023, the Company granted warrants as stock-based compensations valued at approximately $1.60 per warrant, using a Black-Scholes option pricing model with the following assumptions: stock price of $1.60 per share (based on closing price of the Company’s common stock on the date of grant), volatility of 507%, expected term of three years, and a risk free interest rate of 4.47%. As of December 31, 2024 and 2023, there were 20,000 and 20,000 Stock-Based Compensation Warrants issued and outstanding, respectively. A summary of the status of the Company’s total outstanding warrants and changes during the year ended December 31, 2024 is as follows:
|  | Number of Warrants |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Life (Years) |
Balance at January 1, 2023 |  |  | 7,654,572 |  |  | $ | 2.83 |  |  |  | 3.15 |
Granted |  |  | 20,000 |  |  |  | 1.65 |  |  |  | 3.00 |
Exercised |  |  | (105,000 | ) |  |  | 1.75 |  |  |  | — |
Balance outstanding and exercisable at December 31, 2023 |  |  | 7,569,572 |  |  | $ | 2.85 |  |  |  | 2.15 |
Balance at January 1, 2024 |  |  | 7,569,572 |  |  | $ | 2.85 |  |  |  | 2.15 |
Granted (1) |  |  | 1,288,498 |  |  |  | 2.01 |  |  |  | 1.93 |
Exercised |  |  | (48,550 | ) |  |  | 1.75 |  |  |  | — |
Balance outstanding and exercisable at December 31, 2024 |  |  | 8,809,520 |  |  | $ | 2.73 |  |  |  | 1.26 |
(1) Warrants issued related to the Progressive Care Merger on October 1, 2024. As of December 31, 2024, and December 31, 2023, there were 8,809,520 and 7,569,572 warrants outstanding, respectively. As of December 31, 2023, the Company had registered warrants of 2,386,092 of the 7,569,572 warrants issued and outstanding. As of December 31, 2024, the Company had registered warrants of 2,386,092 of the 8,809,520 warrants issued and outstanding. The Company determined that the warrants do not meet the definition of liability under FASB ASC Topic 480 and therefore classified the warrants as equity instruments.

X
- Definition Disclosure for warrants. + References No definition available. + Details
Name: | nxpl_WarrantsDisclosureTextBlock
Namespace Prefix: | nxpl_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration